Lupin Limited announced on March 31, 2026, that it has secured tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection. The product, available in two strengths, is bioequivalent to Merck’s Bridion® Injection. This approval supports Lupin’s growth strategy in the critical U.S. specialty generics market, focusing on advanced injectable products for surgical use.
Lupin Secures Tentative U.S. FDA Approval
Pharmaceutical major Lupin Limited confirmed on March 31, 2026, that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA). This approval is for Lupin’s Abbreviated New Drug Application (ANDA) concerning its Sugammadex Injection.
The approved products cover two specific dosage strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in Single-Dose Vials. Lupin is positioning this generic equivalent as a cost-effective alternative to an existing branded medication in the U.S. market.
Product Indication and Bioequivalence
The U.S. FDA has tentatively approved Lupin’s Sugammadex Injection as bioequivalent to Merck’s Bridion® Injection. This medication is crucial for the reversal of neuromuscular blockade that is induced by rocuronium bromide and vecuronium bromide.
The intended patient population for this reversal agent includes adults and pediatric patients aged 2 years and older who are undergoing surgery. Securing this tentative approval is a key milestone for Lupin’s presence in complex injectables within the highly regulated U.S. healthcare sector.
About the Company’s Global Footprint
Lupin Limited is highlighted as a global pharmaceutical leader headquartered in Mumbai, India, distributing products across over 100 markets. The company specializes in a wide range of pharmaceuticals, including branded generics, complex generics, and biotechnology products.
Lupin maintains a significant operational scale, featuring 15 state-of-the-art manufacturing sites and 7 research centers worldwide. The firm employs a workforce exceeding 22,000 professionals globally. Lupin continues to focus on enhancing patient health outcomes through its diverse subsidiaries, including Lupin Diagnostics and Lupin Digital Health.
Source: BSE
